Incyte Corp. has synthesized diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
Angel Pharmaceuticals Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Researchers from Wayshine Biopharm Holding Ltd. published new data regarding the preclinical systemic pharmacokinetics (PK), dose proportionality, and central nervous system (CNS) distribution of the novel ataxia telangiectasia mutated (ATM) inhibitor WSD-0628, being developed for the treatment of brain tumors.
Researchers from Changzhi Medical College and affiliated organizations presented the discovery of DYC-1, a novel dual-target inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and histone deacetylase 8 (HDAC8), being developed for the treatment of hepatocellular carcinoma (HCC).
Cellular immunotherapy is the Lamine Yamal of cancer therapy. It is easy to forget how young the field is – and that as stunning as it is to watch in action already, it is still reaching its full potential. One aspect of doing so is working in a broader range of tumor types. The field made a giant step toward that goal with last week’s approval of Tecelra (afamitresgene autoleucel, Adaptimmune Therapeutics plc), the first CAR T cell to be approved for treatment of a solid tumor.
Johns Hopkins University has discovered daunorubicin derivatives reported to be useful for the treatment of cancer, including glioblastoma, diffuse midline glioma and diffuse intrinsic pontine glioma.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to RACα serine/threonine-protein kinase AKT targeting moiety through a linker reported to be useful for the treatment of prostate cancer.
Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have described cyclin-dependent kinase 12 (CDK12) inhibitors reported to be useful for the treatment of cancer.
RSS
